Biotherapeutics News and Research

RSS

Mayo Clinic, Terasaki Institute announce research collaboration for improving organ transplant outcomes

Mayo Clinic and Terasaki Institute for Biomedical Innovation announced today a research collaboration centered on improving organ transplant outcomes.

4 Apr 2024

New immunotherapy strategy potentially lays the groundwork for treating autoimmune diseases

Mayo Clinic scientists have developed an immunotherapy strategy that potentially lays the groundwork for treating a spectrum of autoimmune diseases.

1 Apr 2024

Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip

An interview with Abidemi from at the Wyss Institute.

From Society for Laboratory Automation and Screening (SLAS) 18 Mar 2024

Study analyzes the use of tissue-agnostic therapeutics in patients with primary brain tumors

Researchers from Miami Cancer Institute, part of Baptist Health South Florida, today published a study in Trends in Cancer that analyzes the use of tissue-agnostic therapeutics in patients with primary brain tumors (PBTs).

19 Jan 2024

Overcoming adherence challenges: Innovative patch enables controlled drug delivery

A breakthrough in transdermal drug delivery.

17 Jan 2024

Stem cell therapy trial shows promise for regenerative treatment of heart failure

Stem cell-based therapy improved quality of life for patients with advanced heart failure, Mayo Clinic researchers and international collaborators discovered in a late-stage multinational clinical trial.

12 Dec 2023

Small molecule applications of process Raman spectroscopy

In this interview, Kevin Broadbelt of Thermo Fisher Scientific discusses the small molecule applications of process Raman spectroscopy.

From Thermo Fisher Scientific – Portable and Handheld Raman Spectroscopy 11 Dec 2023

New drug shows promise for epilepsy patients with resistant seizures

In cases where standard therapies fail, a medication called XEN1101 reduces seizure frequency by more than 50% in some patients and sometimes eliminates them altogether, a new study shows.

9 Oct 2023

Could baseline gut microbiota predict the immune responses elicited by COVID-19 vaccines?

Researchers characterized the gut microbiota composition associated with the durability of COVID-19 vaccine-induced immunity.

27 Sep 2023

CST and Leica Biosystems partner to enable companion diagnostics for personalized medicine

Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, is partnered with Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging, to support the development of companion diagnostics (CDx) assays using the extensive portfolio of best-in-class antibodies from CST validated for immunohistochemistry (IHC).

From Cell Signaling Technology 20 Sep 2023

Big Tuna and automated buffer exchange: An interview with Unchained Labs

In this interview, AZoNetwork speaks with Joe Barco, the Senior Director of Workflow Marketing at Unchained Labs, about the benefits of automated buffer exchange with Big Tuna.

From Unchained Labs 4 Sep 2023

Study shows that CD98hc can be targeted to deliver biotherapeutics in brain

Researchers engineered and characterized a blood-brain barrier transport vehicle targeting the CD98 heavy chain of heterodimeric amino acid transporters.

24 Aug 2023

Study finds way to reverse gene silencing in inner ear cells

A deafened adult cannot recover the ability to hear, because the sensory hearing cells of the inner ear don't regenerate after damage.

14 Aug 2023

MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to Vittoria Biotherapeutics.

From MaxCyte, Inc. 10 Aug 2023

Fecal transplants safe and effective in treating advanced melanoma, clinical trial shows

In a world-first clinical trial published in the journal Nature Medicine, a multi-center study from Lawson Health Research Institute, the Centre hospitalier de l'Université de Montréal and the Jewish General Hospital (JGH) has found fecal microbiota transplants (FMT) from healthy donors are safe and show promise in improving response to immunotherapy in patients with advanced melanoma.

7 Jul 2023

Study finds the risk of recurrence of active disease in older patients with MS after discontinuing therapy

An article published today in the journal Lancet Neurology evaluates the risk of recurrence of active disease in older patients with multiple sclerosis after discontinuing disease-modifying therapies.

23 Jun 2023

A more aggressive FTC is starting to target drug mergers and industry middlemen

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration's push for lower drug prices at the pharmacy counter.

22 May 2023

Novel gene-editing strategy harnesses an unusual protective ability to eliminate HIV-1 infection

Genetic alterations that give rise to a rare, fatal disorder known as MOGS-CDG paradoxically also protect cells against infection by viruses.

19 May 2023

LabGenius Debuts T-cell Engager Optimisation Capability That Yields Molecules with >400-fold Tumour Killing Selectivity Versus Clinical Benchmark

Through a recent platform demonstration project, LabGenius’ machine learning-driven lead optimisation capability delivered dozens of novel T-cell engagers with best-in-class killing selectivity.

From LabGenius 16 May 2023

MHRA research evaluates two different approaches to cancer therapies

The report 'Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue', published in the PLOS ONE journal, highlights MHRA research which showed that genetic engineering of antibodies used to activate and support the immune system against cancer leads to improvements in their reliability and effectiveness.

13 Apr 2023